FlyteHealth

We’re a proud leader in tech-enabled medical care for people with obesity and comorbid health conditions. Today, we are rebranding as FlyteHealth for our customer and consumer-facing brand. “As our business in the care and navigation of the best-in-class obesity medicine program continues to grow, employers, payers and patients have come to know us as Flyte. With that increased visibility, we are consolidating under FlyteHealth as a single brand,” our CEO and co-founder Sloan Saunders explains. “This alignment allows us to continue to expand our offerings with our partners and provide a unified experience.” Powered by the patent-pending Flyte Intelligence platform, FlyteHealth delivers a user-friendly experience through the FlyteHealth app, care by a team of obesity medicine experts, and patient navigation services. The FlyteHealth approach is built upon the largest data set of obesity and chronic disease research available, as well as the decades of clinical experience of FlyteHealth’s founders — obesity medicine specialists who were among the first to see obesity not as a simple issue of willpower but as a complex disease that requires expert medical treatment. To learn more about our delivery of cost-effective care for obesity and related conditions, visit https://lnkd.in/gKdCZJwf.

Every employer is making difficult decisions about medical obesity treatment. FlyteHealth is honored to be a part of Digital Health New York's obesity working group and is proud that DHNY is a leader in empowering employers to consider comprehensive obesity care. Check out DHNY's Obesity Management Framework, a collaboration between the DHNY obesity working group and Milliman: https://lnkd.in/gzC7HXUH.

Will you be at the Digital Health New York #party in #NewYorkCity next week? Sloan Saunders and I will be representing FlyteHealth. Send us a message if you'd like to #connect. Bunny Ellerin - Anand Gan - Benjamin Maisano - Brenton Fargnoli, M.D. - Chethan Sarabu, MD, FAMIA, FAAP - Jennifer Newman - Mark Kolb - Rachel Day MD, FAAD - Wendy Diller - Archelle Georgiou, MD

Meet more of our obesity experts! Our own Amy Laktash MSN, APRN, NP-C, will present "Muscle Loss Associated with Anti-Obesity Medications" at ObesityLIVE from 5 to 6 p.m. Eastern Aug. 1. ObesityLIVE is a monthly interdisciplinary, multi-institutional, case-based virtual discussion on current and emerging obesity therapies. Don't miss this opportunity to gain valuable insights and engage with experts in the field! Registration and meeting link: https://lnkd.in/ghxKDUyP

⚡ We are incredibly excited about Black Opal Ventures' Impact Report! The Impact Report outlines the impact of Black Opal Ventures' portfolio companies on health outcomes and initiatives aimed at building a more inclusive venture ecosystem. We're honored to be among Black Opal Ventures' portfolio companies. Head to their website to view the full report ➡️ https://lnkd.in/gxpDAZKb

If you missed the American Diabetes Association's 84th Scientific Sessions, we have some great news - Virtual access is available through Aug. 26, 2024, using your ADA username and password. Learn more: https://lnkd.in/gr-FJHSq

💪 #Muscleloss associated with #obesity #medications is a #hottopic right now! Are you free next Thursday 8/1 at 5pm EST to learn more? 🏃♀️ FlyteHealth's very own Amy Laktash MSN, APRN, NP-C will review a #fascinating #case of a #patient who presented to us with severe, debilitating #sarcopenia and #neurologic #complications from #rapidweightloss. 🏋♀️ We can't wait for an #eyeopening conversation with #experts in the field. 🙏 Thank you W Scott Butsch for inviting us to present at your Cleveland Clinic ObesityLIVE #webinar! DETAILS Thursday, August 1st 5-6pm EST Link to join webinar: https://lnkd.in/gRk4ZWCv **CME and MOC available We hope you can join: 💙 Louis Aronne, Leon Igel, MD, FACP, FTOS, DABOM, Jerusha Stahl, Ilana Redmond, Kajal Zalavadia MD DABOM, Jennie Stanford, MD, FAAFP, DipABOM, Nathan Lesch, MSN, FNP-C, BC-ADM, CDCES, Cathy Del Buono, Mackenzie Shireman DNP, RN, NP-C, Julie Trainor, Jessica Fields, Megan Purcell MSN, APRN, FNP-C, RD, LD, CSOWM, NBC-HWC, Morgan Dickison, MS, RD, CSOWM, CDN, Julie Schwartz, Greta Kollmann, MS RD CSOWM CSO CDCES NASM-CPT ACE-CHC, Dana Cizinski, Charlotte F. F., Aimee Carignan MS, RDN, LDN, Anita Grinevics MS,RD-AP, Annie Lorenzo, Ania Jastreboff, MD, PhD, Scott Kahan, MD, MPH, Amanda Velazquez, MD, DABOM, Daniel Goldin, M.D., José Orlando Alemán Díaz, Amy Pollack, Barbara Senich and the rest of the FlyteHealth team 💚 #exercise experts including John Jakicic, Renee J. Rogers, PhD, Tim Church, MD, MPH, PhD, Collin Popp, PhD, MS, RD Cleveland Clinic - Cheryl DiMattia - Ricard Corcelles - Roberto Simons-Linares, MD

In this Medscape article recapping the recent American Diabetes Association 84th Scientific Sessions, our co-founder Dr. Louis Aronne presented preliminary results on the effectiveness of tirzepatide at reducing sleep disruptions in patients with obesity and obstructive sleep apnea (OSA). Dr. Aronne believes these trials demonstrate "the treatment of obesity with tirzepatide plus CPAP is really the optimal treatment for obstructive sleep apnea and obesity-related cardiometabolic risks." Read the full recap: https://lnkd.in/gWYNHXUy

When asked by Everyday Health if skipping doses of a GLP-1 works, our co-founder Katherine Saunders, MD, cautioned that in her practice, she has seen patients underestimate how slowly these medications leave their system. “People can get into trouble with this habit given semaglutide and tirzepatide’s long half-lives,” she says. “If someone skips medication for one week in order to eat larger portions, they might get sick if they assume the medication is out of their system and they eat more than they can handle." Read more on her clinically informed thoughts: https://lnkd.in/gmbPm52m

Our co-founder Katherine Saunders, MD, provides her obesity medicine expertise and professional perspective for this Healio article examining a recent study that compared semaglutide and tirzepatide. She cautions that there were many limitations to the study, including the fact that many participants did not receive FDA-approved dosages for obesity. Read more: https://lnkd.in/gp_dD4ve